AstraZeneca has received marketing authorization by the European Commission (EC) for Moventig (naloxegol) has for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). Moventig is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).

The EC marketing authorization applies to all member states of the EU, Iceland, Norway, and Lichtenstein. The drug was approved by the US Food and Drug Administration, as the first once-daily PAMORA for the treatment of OIC in adult patients with chronic non-cancer pain in September 2014.

Moventig is part of an exclusive worldwide licence agreement formed in September 2009 between AstraZeneca and Nektar Therapeutics. The drug was developed using Nektar's oral small-molecule polymer conjugate technology.

Source: AstraZeneca